In its third deal since it emerged from stealth in May 2020, Dyno Therapeutics has entered into a collaboration and license agreement with Roche to develop adeno-associated virus vectors for gene therapies for central nervous system diseases and liver-directed therapies. The deal, which is worth up to US$1.8 B, will utilise Dyno’s CapsidMap™ platform to overcome the limitations of naturally occurring vectors used in current marketed gene therapies, such as Novartis’ Zolgensma® (onasemnogene abeparvovec).